CompletedPhase 1NCT03053466
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Studying Cancer of unknown primary site
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Apollomics (Australia) Pty. Ltd.
- Principal Investigator
- Marietta FrancoApollomics Inc.
- Intervention
- APL-501(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2022
Study locations (5)
- Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
- Cabrini Health Limited, Malvern, Victoria, Australia
- Peter MaCallum Cancer Centre, Melbourne, Victoria, Australia
- Nucleus Network, Melbourne, Victoria, Australia
- Linear Clinical Research, Nedlands, Western Australia, Australia
Collaborators
Novotech (Australia) Pty Limited · Apollomics Inc. (formerly CBT Pharmaceuticals, Inc.)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03053466 on ClinicalTrials.govOther trials for Cancer of unknown primary site
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07524114Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)University Health Network, Toronto
- RECRUITINGNANCT07283939Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment DelaysAlliance for Clinical Trials in Oncology
- RECRUITINGPHASE2NCT06995508Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO TrialRoswell Park Cancer Institute
- RECRUITINGPHASE1NCT06868433TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CancerEmory University
- RECRUITINGPHASE3NCT06589804Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentNational Cancer Institute (NCI)
- RECRUITINGNANCT06662058Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or RadiationEmory University
- RECRUITINGPHASE2NCT06636734Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP TrialEmory University
- RECRUITINGNANCT06644716[18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary OriginErasmus Medical Center